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An important characteristic of tumors is that they at some point in their development overcome the surveillance of the immune system. Tumors
secrete exosomes,multivesicular bodies containing a distinct set of proteins that can fuse with cells of the circulating immune system. Purified exosomes
from TS/A breast cancer cells, but not non-exosomal fractions, inhibit (at concentrations of nanograms per ml protein) IL-2-induced natural killer (NK)
cell cytotoxicity. The dietary polyphenol, curcumin (diferuloylmethane), partially reverses tumor exosome-mediated inhibition of natural killer cell
activation, which is mediated through the impairment of the ubiquitin–proteasome system. Exposure of mouse breast tumor cells to curcumin causes a
dose-dependent increase in ubiquitinated exosomal proteins compared to those in untreated TS/A breast tumor cells. Furthermore, exosomes isolated
from tumor cells pretreated with curcumin have a much attenuated inhibition of IL-2 stimulated NK cell activation. Jak3-mediated activation of Stat5 is
required for tumor cytotoxicity of IL-2 stimulated NK cells. TS/A tumor exosomes strongly inhibit activation of Stat5, whereas the tumor exosomes
isolated from curcumin-pretreated tumor cells have a lowered potency for inhibition of IL-2 stimulated NK cell cytotoxicity. These data suggest that
partial reversal of tumor exosome-mediated inhibition of NK cell tumor cytotoxicity may account for the anti-cancer properties of curcumin.
© 2007 Elsevier B.V. All rights reserved.Keywords: Breast tumor exosomes; Ubiquitination; NK immunosuppression; Curcumin1. Introduction
The identification of tumor antigens and subsequent produc-
tion of tumor-specific antibodies is of special interest to many
oncologists for both tumor detection and as a means for targeting
the tumor with therapeutic agents [1–7]. This, of course, begs the
question of why the host immune system does not recognize the
tumor in the first place or loses the capacity to recognize the
tumor?Recently, the idea that cancermay represent a failure of the
immune system has re-emerged [1,3]. A potential mechanism for
this is the secretion of a specific vesicular fraction (exosomes) by
the tumor that fuses with natural killer (NK) cells and T cells and
inhibits their responses to activation, thereby creating an immune⁎ Corresponding author. University of Alabama at Birmingham, Birmingham,
AL 35294-0007, USA. Tel.: +1 205 975 9940.
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doi:10.1016/j.bbamcr.2007.04.015tolerance [8]. This mechanism permits a scenario whereby the
loss of defense to the tumor can occur at any time, perhaps related
to regulation of the amount and composition of the exosomes by
the tumor and other external factors.
Exosomes represent a population of membrane vesicles that
are homogenous in size (ranging from 60 to 100 nm) and shape.
They are formed initially by inward budding of the limiting
membrane into the lumen of endosomes, creating multi-vesicular
endosomes. The exosomes are most likely secreted into the
extracellular environment upon fusion of the multi-vesicular
endosomes with the plasma membrane [9]. A recent study has
demonstrated a role for exosomes in the modulation of immune
functions [8]. Exosomes from the serum of pregnant women can
suppress the expression of important T-cell signaling components
including CD3-ξ and JAK3 [54]. Exosomes were also shown to
play a role in the control of tumor growth. Pretreatment of mice
with exosomes derived from murine mammary carcinomas
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activity of NK cells [8].
The anticancer potential of curcumin in various systems has
been studied extensively [10–15]. Curcumin has been shown to
block transformation [16], tumor initiation [17–19], tumor
promotion [20–23], invasion [24–26], angiogenesis [27–30],
and metastasis [11,31–33] through a variety of mechanisms
including regulation of transcription factors such as suppression
of NF-κB, AP-1, and beta catenin activation [34–37]; blocking
proteasome activity [38–42]; and inhibition of the cell cycle
[26,43–46]. Here, we show that curcumin reverses tumor exo-
some-mediated inhibition of NK cell cytotoxicity. Curcumin
treatment of tumor cells leads to enhancement of ubiquitination
of exosomal proteins, further reducing their biological activity
to inhibit NK cell tumor cytotoxicity.
2. Materials and methods
2.1. Cell culture
The TS/A cell line, a moderately differentiated and immunogenic murine
mammary adenocarcinoma of spontaneous BALB/c origin (MHC class I+, H-2Dd,
H-2Kd) wasmaintained in vitro at 37 °C in a humidified 5%CO2 atmosphere in air
in complete medium (DMEM with 5% FCS) as described previously [8]. B16
melanoma cells were obtained from the ATCC and maintained in the ATCC-
recommended media supplemented with 10% FBS. 4T.1 murine mammary tumor
cells were a gift from Dr. Theresa V. Strong (University of Alabama at Bir-
mingham), and were cultured in DMEM media supplemented with 10% FBS.
NK cells were prepared by depletion of splenocytes of all other cell types via
MACS beads (NK isolation kit, Miltenyi Biotech, Auburn, CA) with a typical
yield of N90% CD49b-positive NK cells. NK cells were then cultured in IMDM
supplemented with 50 μM 2-ME, 10% heat-inactivated FCS in the presence of
recombinant IL-2 (100 U/ml, R&D Systems, Minneapolis, MN) before using.
2.2. Polyphenols
Polyphenols including curcumin (diferuloylmethane), genistein (5,7,4′-
trihydroxyisoflavone), quercetin (3,5,7,3′,4′-pentahydroxyflavone), calycosin,
and biochanin A (7,3′-dihydroxy-4′methoxyisoflavone) were purchased from
Sigma (St. Louis, MO). Baicalein (5,6,7-trihydroxyflavone) was purchased from
Cayman Chemical Company (Ann Arbor, Michigan). All stocks were dissolved
in DMSO and stored at −20 °C until used.
2.3. Preparation of exosomes
For preparation of exosomes, TS/A, 4T.1, and B16 cells were cultured in vitro
at 37 °C in a humidified 5% CO2 atmosphere in air in complete medium (DMEM
with 5% FCS that had been centrifuged for 16 h at 141,000×gmax to exclude
bovine exosomes). The supernatants were harvested from these cells after 48 h in
culture. The exosomes were purified from the supernatants by differential
centrifugation as described previously [8]. After differential centrifugation,
exosomes were sedimented at the final centrifugation step and were resuspended
in PBS and re-sedimented at 70,000×gmax. Sedimented exosomes were
resuspended in 5 ml of 2.6 M sucrose, 20 mM Tris–HCl, pH 7.2, and floated
into an overlaid linear sucrose gradient (2.0–0.25 M sucrose, 20 mM Tris–HCl,
pH 7.2) in an SW41 tube for 16 h at 270,000×gmax to remove non-membranous
protein (complexes). Gradient fractions (1ml) were collected via the bottom of the
tube and washed with PBS by centrifugation at 70,000×gmax for 1 h. Finally, the
exosomes (fraction 3) were resuspended in PBS. Fractions 6 and 7, which
contained non-membrane protein complexes, were collected and concentrated
using a protein concentrator with a 100-kDa cutoff (100 kDa MWCO, Amicon).
Fractions 6 and 7 were used as an exosome control (E-control). The protein
content of the exosome and E-control was determined using a BCA protein assay
kit (Bio-Rad, Hercules, CA). Aliquots of each fraction were stored at −80 °C
before examination for the presence of exosomes by electron microscopy.2.4. NK cell proliferation assay
NK cell proliferation was determined using a 3H-thymidine incorporation
assay as described previously [47]. In brief, NK cells (1×104/well in 96-well
plates) were stimulated with IL-2 (100 U/ml) for various times with or without
tumor exosomes. Plates were then pulsed with 1 μCi of [3H]-thymidine (NEN,
Boston, MA) and harvested after 14 h onto glass-fiber mats; incorporation of
radiolabeled thymidine into DNAwas determined using a scintillation counter.
2.5. NK-cell cytotoxicity
Spleen NK cells were dispensed into a 96-well microtitre plate. Cells were
cultured in theRPMI1640 supplementedwith 10%FBSand IL-2 (100U/ml) for 1 to
3 days in the presence of different concentrations of tumor exosomes. Specific NK-
cell cytotoxic activities were determined using a standard 4 h chromium release
assay as described previously [47]. Briefly, spleen NK cells were plated in triplicate
in 96-well U-bottom culture plates (Corning Glass, Corning, NY) and co-cultured
for 4 h with sodium 51Cr-chromate-labeled (100 μCi; NEN, Boston, MA) TS/A
tumor cells. Supernatants were collected, radioactivity measured, and the specific
lysis calculated according to the following equation: percentage of specific cyto-
toxicity=(experimental cpm−spontaneous cpm)/(maximum cpm−spontaneous
cpm)×100. Maximum chromium release was determined from supernatants of
lysed target cells incubated with Triton X-100 (5% v/v). Spontaneous release was
determined from target cells incubated without added effector cells.
2.6. Immunoblot analysis
Western blot analysis of proteins expressed in NK cells treated with tumor
exosomes was carried out using a method as described previously [8]. In brief, NK
cell lysateswere boiled in SDS sample buffer, and 50μg of total proteinwas loaded
into each well of an SDS-gel for separation by PAGE. The proteins were then
transferred onto nitrocellulose membranes, and the blotted membranes blocked for
1 h with PBS-Tween 20 (0.25M Tris, pH 7.5, PBS, 150 mM sodium chloride, and
0.2%Tween 20) containing 5%BSA. Blots were then probed overnight with 1 μg/
ml of a primary Ab, washed three times with PBS-Tween 20 and then probed for
1 h with the appropriate Alexa Fluor 680 (Molecular Probes) or IRdye 800
(Rockland Immunochemicals). conjugated secondary Ab. After three washes with
PBS-Tween 20, blotted proteins were detected and quantified using an Odyssey
infrared imaging system (LI-COR, Lincoln, NE). The following antibodies were
used for the western blots: anti-multiubiquitinated protein monoclonal antibodies
FK2 (dilution,MBL,Woburn,MA),β-actin (1:5000, Sigma, St. Louis, MO), Jak3
and Jak1 (1:1000; BD Pharmingen, San Diego, CA), and phosphorylated Stat5
(1:500; BD Pharmingen, San Diego, CA).
2.7. Labeling TS/A exosomes
The PKH67 kit was used for labeling TS/A tumor exosomes according to the
manufacturer's instructions (Sigma). The protocol has been described in detail
previously [8]. In brief, 1 μg of TS/A tumor exosomes in 100 μl of PBS were
resuspended in 1 ml Diluent C. The exosomes were mixed rapidly with a freshly
prepared PKH67 solution in Diluent C (final concentration during labeling step:
5×10-6 M) and incubated for exactly 3 min to ensure homogeneous staining.
The labeling step was stopped by addition of an equal volume of FBS for 1 min,
followed by an equal volume of complete DMEM medium. After three washes
in PBS by ultracentrifugation, the exosomes were resuspended in 100 μl of
complete culture medium containing FBS and enumerated. All the staining
procedures were carried out at 22 °C.
2.8. Internalization of exosomes by NKs
TS/A exosomes were labeled with PKH67 as described above, mixed with
1×106 spleenNK cells (30min at 37 °C). The uptake of exosomes byNK cells was
stopped bywashing in cold PBS, transferred onto a glass slide, followed by fixation
in PF and determination of TS/A exosomes transfection efficiency through
visualization using a Leica TCS-NT confocal microscope (Leica Microsystems,
Deerfield, IL). To quantify the efficiency of exosomes uptaken by NK cells, five
fields were randomly selected on each slide, and the average number of green
fluorescent positive NK cells was determined by adding the total number of green
fluorescent positive NK cells, then dividing by total number of cells in five fields.
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All results are expressed as the mean±SEM. The statistical significance was
assessed using one-way ANOVA with the Bonferroni correction.
3. Results
3.1. Tumor exosomes inhibit IL-2 stimulated NK cell tumor
cytotoxicity
To determine which fraction collected from the sucrose-
gradient had inhibitory activity on NK cell functions, each
fraction was analyzed for its inhibition of the proliferation ofFig. 1. TS/A breast tumor exosomes inhibit IL-2 stimulated NK cell activation and tum
different fractionated samples (100 ng/ml) harvested from sucrose gradients of TS/A s
(A) IL-2 stimulated NK Tcell-proliferative response was measured using a 3H-thymid
to 51Cr-labeled TS/A cells at varying effector/target ratios as indicated. The amount
release was calculated. Data are presented as the mean±SEM of triplicate wells repre
tumor exosome treated NK cells tumor cytotoxicity that was significantly differentNK cells isolated from BALB/c mice and tumor cytotoxicity
against TS/A tumor cells. The effects of different fractions were
compared with those elicited by an exosomes-depleted fraction
(E-controls). Fraction 3, containing exosomes as shown by
electromicroscopy (Fig. 1A, insert), strongly inhibited the
proliferation of IL-2 stimulated NK cells in comparison with
other fractions (Fig. 1A, Pb0.001). The results of the 4 h 51Cr
release assay also indicated that fraction 3 prevented IL-2
activated NK cells from killing 51Cr labeled TS/A tumor cells
(Fig. 1B). Similar results were obtained with exosomes of 4T.1
breast tumor cells (Fig. 1C) and B16 melanoma tumor cells
(Fig. 1D).or cytotoxicity. Splenic DX5+ NK cells were cultured with IL-2 (100 U/ml) with
upernatants prepared as described in Materials and methods. At day 3 of culture,
ine uptake assay after an 18-h pulse of 3H-thymidine; or (B) NK cells were added
of 51Cr released into the supernatant was determined, and the percent specific
sentative of three independent experiments. The asterisk above the bar indicates
from the E-control treated NK cells. *Pb0.05, **Pb0.01.
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suppression of NK cell tumor cytotoxicity
In the first test of the hypothesis that dietary polyphenols can
reverse the inhibitory effects of tumor exosomes on NK cell
tumor cytotoxicity, five different polyphenols (1 μM) were
examined. Thirty-six h after addition of each polyphenol to TS/
A tumor cell cultures, the exosomes were sucrose gradient-
purified and reversal of the inhibitory effect of TS/A tumor
exosomes on NK cell cytotoxicity against TS/A tumor cells was
examined. The NK cell cytotoxicity was calculated using a
formula as described in Materials and methods. The effects of
exosomes isolated from the TS/A tumor cells treated with
different polyphenols or with polyphenol carrier (DMSO) at the
same concentration used as the solvent in NK cell tumor
cytotoxicity assays were compared with the cells treated E-
control isolated from the DMSO treated TS/A tumor cells. Of
these, curcumin had the strongest effects on NK cell killing 51Cr
labeled TS/A tumor cells although among five polyphenols
tested, three polyphenols have significant effects on the reverse
of tumor exosome-mediated inhibition of NK cell tumor
cytotoxicity. At ratios of 20 : 1 (IL-2 stimulated NK cells :
TS/A tumor cells), the percentages of tumor cytotoxicity caused
by NK cells increased significantly from 5.2±1.1% (E-control)
to 22.4±4.2% (Pb0.01), 14.8±3.8% (Pb0.05), 10.2±1.8%
(Pb0.05), and 6.70±0.6% (PN0.05) when TS/A exosomes
purified from TS/A tumor cells pretreated with curcumin,
baicalein, genistein, and DMSO (carrier control), respectively.
Other polyphenols including biochanin A and quercetin tested
had no significant effects on TS/A tumor exosome-mediated
inhibition of NK cell tumor cytotoxicity (data not shown). Use
of a wider range of concentrations revealed that the effect of
curcumin was dose-dependent and that even at 200 nM it caused
a significant attenuation of TS/A tumor exosome-mediatedFig. 2. Curcumin treatment of TS/A tumor cells reduces TS/A tumor exosome-medi
cells are cultured for 36 h in the presence of different concentrations of curcumin or th
of curcumin. Exosomes were sucrose-gradient purified from the supernatants. Spleen
A tumor exosomes for 3 days. NK cell proliferation (A), and tumor cytotoxicity of NK
of NK cell cytotoxicity (A) or [3H]-thymidine incorporation (B, C) of the cells treated
presented as the mean±SEM of five wells representative of three independent expeinhibition of NK cell tumor cytotoxicity (Pb0.05, Fig. 2A).
This was also the case for reversing NK cell proliferation at two
different ratios of NK:TS/A cells as indicated by an increase in
[3H]-thymidine incorporation into DNA (Fig. 2B, C).
These data suggest that TS/A tumor cells produce exosomes
that can inhibit NK cell activation and tumor cytotoxicity.
Pretreatment of TS/A tumor cells with curcumin, (200 nM and
above), led to partial reversal of tumor exosomes-mediated
inhibition of NK cell cytotoxicity.
3.3. Curcumin treatment enhances ubiquitination of tumor
exosomal proteins
Inhibition of the proteasome activity was considered as playing
a role in anti-cancer activity of curcumin [40,42,44]. Exosomal
proteins are regulated by the ubiquitin pathway [48–51];
therefore, we investigated whether curcumin treatment had an
effect on the ubiquitination of tumor exosomal proteins. Western
blot analysis of exosomes purified from TS/A tumor cell cultured
supernatants indicated that curcumin treatment of TS/A tumor
cells resulted in the accumulation of ubiquitinated proteins in the
exosomes. Accumulation of the ubiquitinated TS/A exosomal
proteins is curcumin dose-dependent (Fig. 3A). Differences in
signal intensity of ubiquitinated exosomal proteins are unlikely to
be due to uneven loading of protein as there was no differences in
the amounts of CD9 (one of the exosomal protein markers—see
Fig. 3A, bottom panel). To determinewhether the accumulation of
ubiquitinated exosomal proteins as a result of curcumin treatment
was associated with the enhancement of NK cell tumor cyto-
toxicity, NK cell cytotoxicity against TS/A tumor cells was
examined. TS/A tumor exosomes were isolated from the super-
natants of TS/A tumor cells treated with different concentrations
of curcumin and used for pulsing primary NK cells isolated from
the spleens of 2-month-old BALB/c mice. After incubation withated inhibition of NK cell activation and tumor cytotoxicity. TS/A breast tumor
e solvent DMSO at the same concentration as used for the highest concentration
NK cells were stimulated with IL-2 (100 U/ml) in the presence or absence of TS/
cells (B) were analyzed using methods as described in Fig. 1 legend. The ratios
with TS/A exosomes versus treated with E-control were calculated. The data are
riments. *Pb0.05, **Pb0.01.
Fig. 3. Curcumin treatment of TS/A breast tumor cells increases ubiquitinated exosomal proteins without affecting the entry of exosomes. TS/A tumor cells were
cultured in the presence of different concentrations of curcumin for 36 h. Exosomes were purified from the supernatants by sucrose gradient. The exosomes were lysed
and analyzed for ubiquitinated proteins by western blot with a mouse anti-polyubiquitin antibody (A, the top panel), or a mouse anti-CD9, which is one of exosomal
protein markers (A, the bottom panel). To determine the effects of curcumin treatment on the attenuation of TS/A tumor exosome-mediated inhibition of NK tumor
cytotoxicity, spleen DX5-positive NK cells were stimulated with IL-2 (100 U/ml) in the presence of TS/A exosomes (100 ng/ml) or E-control (100 ng/ml) for 24 h.
Tumor cytotoxicity of NK cells was analyzed using methods as described in Fig. 1 legend. The ratios of NK cell cytotoxicity of the cells treated with TS/A exosomes
versus E-control were calculated. The data are presented as the mean±SEM of five wells representative of three independent experiments (B). TS/A exosomes were
labeled with PKH67 dye as described in Materials and methods. Purified spleen NK cells (1×104) were stimulated with IL-2 (100 U/ml) in the presence of PKH67+
TS/A exosomes (100 ng/ml) isolated from the TS/A tumor cells cultured with different concentrations of curcumin. TS/A exosome-treated NK cells were then
harvested at 6 h and unbound exosomes were washed three times with PBS. The cells were centrifuged onto poly-L-lysine-coated slides and examined for green
fluorescent labeled NK cells using a Leica confocal microscope: ×60 (B, insert). Percentages of PKH67+ cells were calculated by counting the total number of PKH67+
NK cells, then dividing by the total number of cells in five randomly selected fields. The result is expressed as the mean±SEM of the results of assays performed in
triplicate. The data are representative of 4 independent experiments (C). *Pb0.05, **Pb0.01.
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(100 U/ml), the NK cells were then washed 3 times with PBS to
remove unbound exosomes before the cells were used in a
standard in vitro chromium release assay. The addition of tumor-Fig. 4. Reduction in inhibition of Jak3 expression of IL-2 stimulated NK cells by TS/A
were cultured in the presence of different concentrations of TS/A exosomes purified
NK cells were lysed after 72 h in culture. Fifty μg of total protein from each lysate
nitrocellulose membrane, the blots were probed with the indicated antibodies (A). T
infrared imaging system (LI-COR). The ratios of signal intensity of each protein te
calculated and plotted (B). The data are representative of three independent experimderived exosomes strongly inhibited the NK cell-mediated killing
of TS/A target cells (Fig. 3B). At a 20:1 E:T ratio, there was a 80±
7% reduction in the cytotoxic activity of the exosome-treated NK
cells as compared to theNK cells that had been treatedwith PBS astumor exosomes produced in the presence of curcumin. Spleen DX5+ NK cells
from the supernatants of TS/A cells pretreated with curcumin (0.8 μM) for 36 h.
were resolved on a 10% SDS PAGE gel. After proteins were transferred to a
he signal intensity of each protein analyzed was quantified using an Odyssey
sted in DMSO treated TS/A exosomes:curcumin treated TS/A exosomes were
ents. **Pb0.01.
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tumor cells pretreatedwith cucumin led to a significant attenuation
of TS/A tumor exosome-mediated inhibition of NK cell tumor
cytotoxicity in a curcumin dose dependent manner (Fig. 3B). The
attenuation of TS/A exosomes mediated inhibition of NK cell
cytotoxicity appears to be associated with the enhancement of
ubiquitination of exosomal proteins.
Furthermore, the results of NK cells pulsed with PKH67
fluorescently labeled TS/A exosomes indicate that TS/A exo-
somes are effectively taken up by NK cells (N84±5.6%) regard-
less of whether TS/A tumor cells were treated with curcumin or
DMSO as a carrier control (Fig. 3C). These data suggest that
regardless of the treatments, NK cells have equal opportunity to
uptake tumor exosomes.
3.4. Curcumin pretreatment of exosomes isolated from tumor
cells lowers the inhibition of Jak3 activation in IL-2 stimulated
NK cells
Our previous data suggest that expression of Jak3, but not
Jak1, was inhibited by tumor-derived exosomes [8]. To
determine if curcumin reversal of tumor exosome-mediated
inhibition of NK cell activation and cytotoxicity was associated
with the inhibition of Jak3 expression, the expression of Jak3
and Jak3 regulated molecules were quantified by western blot
analysis. We found that the expression of Jak3 (Fig. 4A, the top
panel), but not Jak1 (Fig. 4A, the third panel from the top), was
inhibited by the tumor-derived exosomes. This inhibition of
Jak3 expression was further demonstrated by a reduction in the
levels of phosphorylated Stat5, which is one of Jak3 substrates
(Fig. 4A, the second panel from the top). In contrast, tumor
exosomes isolated from TS/A tumor cells pretreated with
curcumin have a much less attenuated reduction of both the
expression of Jak3 and p-Stat5. The reversal of reduction of
Jak3 expression and phosphorylation of Stat5 was dependent on
the concentration of curcumin used for treatment of TS/A tumor
cells. The differences in the amount of phosphorylated Stat5
among samples were not attributable to differences in sample
loading as equivalent levels of β-actin were detected (Fig. 4A,
the bottom panel). Further quantification of expression of Jak3
and p-Stat5 indicated that upon treatment of the TS/A tumor
cells with curcumin, TS/A tumor exosome-mediated inhibition
of the expression of Jak3 and p-Stat5 was reversed significantly
(Pb0.01) (Fig. 4B). Pretreatment of TS/A tumor cells with
curcumin had no effect on expression of Jak1 or β-actin
(PN0.05) (Fig. 4B).
4. Discussion
The experiments in the present study have revealed that several
polyphenols derived from the diet, in particular curcumin, can
reverse the immunosuppressive effects ofmousemammary tumor
exosomes on NK cells. To the best of our knowledge, these
findings represent the first example of curcumin treatment that
leads to attenuation of tumor exosome-mediated immunosup-
pression of NK cell activation and tumor cytotoxicity. Blocking
activation of Stat5 of IL-2 stimulated NK cells is considered asone of the mechanisms underlying tumor exosome-mediated
immunosuppression ofNKcell activation [8]. This study suggests
that function of tumor exosomes was altered after tumor cells
were treated with curcumin. The exosomes isolated from the
tumor cells pretreatedwith curcumin cause a significant reduction
of immunosuppression of NK cell activation and tumor cyto-
toxicity. Furthermore, this reduction in immunosuppression was
correlated with enhancement of ubiquitinated exosomal proteins
after tumor cells were treated with curcumin. Taken together, the
data are consistent with the hypothesis that diet is a factor in
determining immune tolerance to tumor cells.
Curcumin, a naturally occurring polyphenolic compound
found in the spice turmeric, has been reported to have many
biological effects. Such a multiplicity of activities could result
from the highly reactive α,β-unsaturated ketone group of cur-
cumin. The ketone group can bind covalently to many proteins
that are involved in proteasome-mediated degradation pathways
[19,38,39,41,52,53] and in particular, those proteins having a
E3 ligase activity. Therefore, the identification of E3 ligase(s)
that are regulated by curcumin and play a critical role in tumor
exosome-mediated immunosuppression should be investigated
further. In addition, this initial finding as reported in this study
opens up the potential strategy to identify tumor exosomal
proteins that are ubiquinated and associated with curcumin
treatment. These proteins most likely play an important role in
tumor exosome-mediated immune suppression. We have failed
to identify such proteins by mass spectrometry analysis as many
exosomal proteins have become ubiquinated after curcumin
treatment of TS/A tumor cells. A suitable method must be
developed for addressing this issue.
Another unsolved question concerns the fact that we do not
currently know whether curcumin treatment results in enhance-
ment of the ubiquitination of house-keeping exosomal proteins
and/or additional cellular proteins sorting into tumor exosomes
as a result of curcumin treatment. One hypothesis is that cur-
cumin may inhibit proteasome activity, facilitating sorting of
ubiquitinated proteins into the exosomes. These proteins co-
exist with tumor exosomal proteins and interfere with their
immununosuppression activity. Alternatively, the immunosup-
pressive activity of tumor exosomal proteins is inactivated once
they are ubiquitinated. Further investigations will be required to
address these points.
The attenuation of tumor exosome-mediated immune sup-
pression by curcumin treatment reported here appears to be in
contrast to previous reports of the ability of curcumin to
suppress immune activity. Other recent studies [55] are in
agreement with our study that suggests that curcumin enhances
NK cell tumor cytotoxicity. The reason for the discrepancies
between our study and earlier studies are numerous. Earlier
reports investigated the direct effect of cucurmin on immune
cells such as T cells, NK cells, and other leukocytes. However,
we determined the effects of exosomes produced by tumor cells
pretreated with curcumin on NK cell tumor cytotoxicity. There-
fore, we did not expect to necessarily observe a similar effect on
cytotoxicity when NK cells were directly treated with curcumin
compared to exosomes mixed with NK cells where the exo-
xomes were produced from treatment of tumor cells with
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target cells used, that is, immune cells versus tumor cells, and
the use of different stimuli in the experiments. For an example,
curcumin treatment of K562 cells does not induce significant
variations in the levels of phosphorylated Stat-5, but curcumin
treatment of TS/A tumor cells leads to a reduction of p-Stat5 as
observed in our work.
Our results suggest that curcumin treatment of tumor cells
leads to the enhancement of ubiquitination of tumor exosome
proteins, and the reduction of tumor exosome-mediated inhibition
of NK cell tumor cytotoxicity. However, due to a 5–10%
contamination of our NK cell populations with non-NK cells, the
possibility of non-NK cells contributing to the tumor exosome-
mediated inhibition of NK cell proliferation and tumor cytotoxi-
city via some interaction with NK cells cannot be excluded.
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